Conversely, though PSP has far fewer patients to enroll in trials and fewer diagnostic and response biomarkers, they are clinically distinct from other neurodegenerative diseases, follow an expected disease course, and almost always have 4R tau pathology on autopsy. The gene discussed is MAPT; the disease is neurodegenerative disease.